Malaysian Genomics Resource Centre Bhd 2017 AR2
The report outlines the financial and operational performance of Malaysian Genomics Resource Centre Berhad (MGRC) for the fiscal year ended June 30, 2017. A key highlight was the 100 percent acquisition of MPath Sdn Bhd, which consolidates Clinipath's clinical pathology services to provide MGRC with recurring revenue. MGRC is strategically shifting its focus from project-based genome sequencing and analysis to genetic screening and clinical pathology services for long-term stability. Additionally, the company continued its corporate social responsibility initiatives, actively supporting NGOs like PERTIWI to assist the homeless and Free Tree Society to promote environmental conservation.
Company: Malaysian Genomics Resource Centre Bhd
Sector: Professional & technical services
Country: Malaysia
Year: 2017
Type: AR2
Pages: 130
Back to company
Malaysian Genomics Resource Centre Bhd
Annual Report
The report outlines the financial and operational performance of Malaysian Genomics Resource Centre Berhad (MGRC) for the fiscal year ended June 30, 2017. A key highlight was the 100 percent acquisition of MPath Sdn Bhd, which consolidates Clinipath's clinical pathology services to provide MGRC with recurring revenue. MGRC is strategically shifting its focus from project-based genome sequencing and analysis to genetic screening and clinical pathology services for long-term stability. Additionally, the company continued its corporate social responsibility initiatives, actively supporting NGOs like PERTIWI to assist the homeless and Free Tree Society to promote environmental conservation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jul 1, 2016 - Jun 30, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board